Hypertension and Diabetic Kidney Disease

Summary

The increase in diabetic kidney disease is a worldwide problem. Current treatment centers on antihypertensives inhibitors for the renin-angiotensin system and merely retards the decline of renal function. A large unmet need thus exists for therapies that fully halt disease progression or provide curative benefit

Highlights

The necessity for aggressive blood pressure control is undisputed in the medical community, but the therapeutic focus is now extending to end-organ protection as a treatment goal of equal importance to BP reduction. Thus, commercial performance of both ACE inhibitors and ARBs is dependent on renoprotective benefits beyond blood pressure controlThe pipeline for developmental drugs targeting the cause of diabetic kidney disease is dominated by endothelin receptor antagonists and advanced glycosylation end product inhibitors. The commercial potential for successful new agents is substantial as existing therapies do not halt the progression of diabetic nephropathy to end stage renal diseaseProximal blockade of the renin-angiotensin system (RAS) through renin inhibition offers greater treatment opportunities than distal inhibition via angiotensin II receptor blockade. Recent basic and clinical research supports the strong theoretical appeal of renin inhibition as the most promising pharmacological strategy in the short-to-medium term

Scope

• The prevalence and progression of diabetic nephropathy in the seven major markets is evaluated
• The foremost pharmacological strategies for the treatment of diabetic nephropathy are reviewed
• The current status of angiotensin II receptor blockade as first line therapy in the treatment of diabetic nephropathy is discussed
• An overview is given of the drugs in development for the treatment of diabetic nephropathy

Reasons to Purchase

• Explore the growing burden of ESRD on healthcare systems through data on the prevalence and progression of diabetic nephropathy
• Assess the potential of current treatment options in the diabetic nephropathy arena
• Identify novel R&D compounds in the diabetic nephropathy pipeline

Content